… ” blood tests are emerging for urothelial cancer aimed at … such tests provide complementary
information: circulating tumor … of a person’s cancer, whereas circulating tumor DNA may be …

… urothelial carcinoma, liquid biopsies such as plasma circulating tumour DNA (ctDNA) and
urinary tumour DNA … multiplex urinary methylation assay named urine tumour DNA methylation …

… of circulating tumor DNA (ctDNA) from the plasma of patients with metastatic bladder cancer
captures the … Control DNA for testing the targeted sequencing panel was extracted from …

… Although to the best of our knowledge no targeted therapies currently are approved for the
treatment of mUC, ctDNA NGS tests can be used for multiple GAs that have matched targeted …

… Our results support the need for further assessment of the clinical utility of NGS testing in
informing treatment decisions for these patients, especially in the current era with multiple …

… biopsy assays to urinary DNA to evaluate urothelial cancer noninvasively (assays summarized
in … UroSEEK has been the most broadly tested and consists of 3 tests, all applied to urine …

… Mantel-Cox log-rank testing assessed the association between … Here, we show that DNA
from upper tract urothelial tumors … tumor DNA can be used to predict that upper tract urothelial …

… , were used to assess circulating tumor DNA (ctDNA) by ultra-… found ctDNA testing in patients
with bladder cancer who … of treatment response, and early detection of metastatic relapse. …

… Personalized, tumor-informed ctDNA assays (Signatera) were designed as previously …
derived from WES of tumor tissue were selected for multiplex PCR (mPCR) testing. mPCR primers …

… monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing
… and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical …